Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure: Conditions:   Nasopharyngeal Carcinoma;   Recurrent Nasopharyngeal Carcinoma;   Metastatic Nasopharyngeal Carcinoma;   Chemotherapy Effect;   Immunotherapy;   Molecular Targeted Therapy

Intervention:   Drug: Apatinib plus Camrelizumab

Sponsor:   Sun Yat-sen University

Recruiting